Tara M Friebel

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers
    Tara M Friebel
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Clin Breast Cancer 7:875-82. 2007
  2. ncbi Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality
    Susan M Domchek
    Abramson Cancer Center and Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    JAMA 304:967-75. 2010
  3. ncbi Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers
    Susan M Domchek
    Abramson Cancer Center, The University of Pennsylvania School of Medicine, 3W Perelman Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Breast Cancer Res Treat 124:195-203. 2010
  4. ncbi Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes
    Timothy R Rebbeck
    Abramson Cancer Center, Center for Clinical Epidemiology and Biostatistics, and Department of Medicine, The University of Pennsylvania Perleman School of Medicine, Philadelphia, Pennsylvania, USA
    Cancer Res 71:5792-805. 2011
  5. ncbi Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study
    Susan M Domchek
    Abramson Cancer Centre, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6021, USA
    Lancet Oncol 7:223-9. 2006
  6. ncbi Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers
    Brian S Finkelman
    Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 217 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104 6021
    J Clin Oncol 30:1321-8. 2012
  7. ncbi Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers
    Timothy R Rebbeck
    Abramson Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    Cancer Res 69:5801-10. 2009
  8. ncbi Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
  9. ncbi Validity of models for predicting BRCA1 and BRCA2 mutations
    Giovanni Parmigiani
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21205 2011, USA
    Ann Intern Med 147:441-50. 2007
  10. ncbi Active recruitment increased enrollment in a hereditary cancer registry
    Tara M Friebel
    Mid-Atlantic Cancer Genetics Network, Department of Pathology, Johns Hopkins University School of Medicine, Park SB202, 600 N. Wolfe St, Baltimore, MD 21287, USA
    J Clin Epidemiol 57:1172-6. 2004

Detail Information

Publications10

  1. ncbi Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers
    Tara M Friebel
    Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Clin Breast Cancer 7:875-82. 2007
    ..The availability of these risk-reduction strategies is an important consideration in the decision to undergo genetic testing...
  2. ncbi Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality
    Susan M Domchek
    Abramson Cancer Center and Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
    JAMA 304:967-75. 2010
    ..Mastectomy and salpingo-oophorectomy are widely used by carriers of BRCA1 or BRCA2 mutations to reduce their risks of breast and ovarian cancer...
  3. ncbi Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers
    Susan M Domchek
    Abramson Cancer Center, The University of Pennsylvania School of Medicine, 3W Perelman Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Breast Cancer Res Treat 124:195-203. 2010
    ..An unacceptably high proportion of pathologic examinations did not adequately examine ovaries and fallopian tubes obtained at RRSO...
  4. ncbi Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes
    Timothy R Rebbeck
    Abramson Cancer Center, Center for Clinical Epidemiology and Biostatistics, and Department of Medicine, The University of Pennsylvania Perleman School of Medicine, Philadelphia, Pennsylvania, USA
    Cancer Res 71:5792-805. 2011
    ..Overall, the data suggest that genomic variation at multiple loci that encode proteins that interact biologically with BRCA1 are associated with modified breast cancer and ovarian cancer risk in women who carry BRCA1 mutations...
  5. ncbi Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study
    Susan M Domchek
    Abramson Cancer Centre, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6021, USA
    Lancet Oncol 7:223-9. 2006
    ..Together, these data could give information to women who are considering genetic testing...
  6. ncbi Breast and Ovarian Cancer Risk and Risk Reduction in Jewish BRCA1/2 Mutation Carriers
    Brian S Finkelman
    Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 217 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104 6021
    J Clin Oncol 30:1321-8. 2012
    ..In particular, 6174delT carriers had a lower risk of breast cancer. This finding requires additional confirmation in larger prospective and population-based cohort studies before being integrated into clinical care...
  7. ncbi Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers
    Timothy R Rebbeck
    Abramson Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
    Cancer Res 69:5801-10. 2009
    ..026). Variants in genes that interact biologically withBRCA1 and/or BRCA2 may be associated with modified ovarian cancer risk in women who carry BRCA1/2 mutations...
  8. ncbi Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
    ....
  9. ncbi Validity of models for predicting BRCA1 and BRCA2 mutations
    Giovanni Parmigiani
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21205 2011, USA
    Ann Intern Med 147:441-50. 2007
    ..At least 7 models for estimating the probabilities of having a mutation are used widely in clinical and scientific activities; however, the merits and limitations of these models are not fully understood...
  10. ncbi Active recruitment increased enrollment in a hereditary cancer registry
    Tara M Friebel
    Mid-Atlantic Cancer Genetics Network, Department of Pathology, Johns Hopkins University School of Medicine, Park SB202, 600 N. Wolfe St, Baltimore, MD 21287, USA
    J Clin Epidemiol 57:1172-6. 2004
    ..6% to 67.4%). CONCLUSION: Allocating research staff specifically for recruitment and personal contact with potential participants is effective in achieving increased enrollment into a national hereditary cancer research registry...